Newer Antidiabetic Drugs (Incretin-based, SGLT2 inhibitors, etc.)
Start with the big picture
The lesson surveys several newer drug groups and connects their mechanisms with clinical effects and safety considerations. GLP-1 receptor agonists enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety; DPP-4 inhibitors prolong incretin activity. SGLT2 inhibitors increase urinary glucose loss by blocking its reabsorption in the proximal tubule. The topic also introduces pramlintide, the dual GIP/GLP-1 agonist tirzepatide, and fixed-ratio basal insulin/GLP-1 combinations. Across these therapies, the source emphasizes differences in weight effects, hypoglycemia risk, adverse effects, and renal considerations. It also frames treatment selection around conditions such as cardiovascular disease, chronic kidney disease, and heart failure, alongside patient preferences and renal function.
What you'll learn
- Explain the mechanisms of GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT2 inhibitors.
- Compare the clinical effects and weight impacts described for newer antidiabetic drug groups.
- Identify key adverse effects and cautions associated with these therapies.
- Describe the roles of pramlintide, tirzepatide, and fixed-ratio basal insulin/GLP-1 combinations.
- Relate comorbidities, renal function, and patient preferences to therapy selection.
Continue your study
Work through the complete notes and reinforce the topic with the study tools available in the full lesson.
